Greg Jones

Greg Jones

Company: Pfizer

Job title: Principal Scientist

Seminars:

Multi-Omics Data Integration Reveals New Targets In RAS-Mutant Cancers Resistant to KRASG12C Inhibition 3:30 pm

In Vivo CRIPSR screens in RAS mutant cell lines models reveal new vulnerabilities for ERK/MAPK addicted cancers KRASG12Ci Resistant cell lines models can be leveraged to reveal treatment emergent vulnerabilities in these cancers Co-Targeting of the RAS and Hippo pathway might provide a rationale therapeutic approach to overcome resistance to RAS targeted therapies with Biomarker…Read more

day: Day Two Track E

Intrinsic & Adaptive Resistance 3:00 pm

Read more

day: Pre-Conference Day Track F

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.